These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 24507065)

  • 1. Temsirolimus as base immunosuppressant for a recipient with metastatic renal cancer: adequate immunosuppression and oncological control--case report.
    Chueh SJ; Sankari BR; Gonzales-Chambers R; Lipscomb L; Africa J; Williams J; Jones AM
    Transplant Proc; 2014; 46(1):271-3. PubMed ID: 24507065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial experience with temsirolimus in 2nd-, 3rd- and 4th-line therapy for metastatic renal cell cancer: good clinical response.
    Kuru TH; Huber J; Hatiboglu G; Wagener N; Pahernik S; Hadaschik B; Hohenfellner M
    Urol Int; 2011; 86(3):256-60. PubMed ID: 21266794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma.
    Stenner-Liewen F; Grünwald V; Greil R; Porta C
    Expert Rev Anticancer Ther; 2013 Sep; 13(9):1021-33. PubMed ID: 24024788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
    Vogelzang NJ; Bhor M; Liu Z; Dhanda R; Hutson TE
    Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
    Fujisaka Y; Yamada Y; Yamamoto N; Horiike A; Tamura T
    Jpn J Clin Oncol; 2010 Aug; 40(8):732-8. PubMed ID: 20430774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R; Boni JP; Ravaud A
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment with sirolimus for an angiomyolipoma mimicking renal cell carcinoma in a transplanted kidney.
    Chiu HF; Wen MC; Li JR; Ho HC; Shu KH
    Transpl Int; 2015 Sep; 28(9):1116-20. PubMed ID: 25790294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.
    Boni JP; Hug B; Leister C; Sonnichsen D
    Semin Oncol; 2009 Dec; 36 Suppl 3():S18-25. PubMed ID: 19963096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
    Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
    J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adverse events associated with temsirolimus for patients with metastatic renal cell carcinoma].
    Miyake H; Fujisawa M
    Hinyokika Kiyo; 2012 Nov; 58(11):651-4. PubMed ID: 23254795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study.
    Mühlbacher F; Neumayer HH; del Castillo D; Stefoni S; Zygmunt AJ; Budde K;
    Transpl Int; 2014 Feb; 27(2):176-86. PubMed ID: 24266855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved outcome after 'bottom-up' immunosuppression in liver transplant recipients with preoperative renal impairment.
    Schnitzbauer AA; Doenecke A; Sothmann JL; Loss M; Farkas SA; Hartl J; Tsui TY; Baier L; Kirchner G; Obed A; Bein T; Geissler EK; Scherer MN; Schlitt HJ
    Eur Surg Res; 2010; 45(3-4):356-67. PubMed ID: 21088426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
    Malizzia LJ; Hsu A
    Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temsirolimus for advanced renal cell carcinoma.
    Bergmann L; Maute L; Guschmann M
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):9-21. PubMed ID: 24313573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temsirolimus in patients with renal cancer on hemodialysis.
    Lunardi G; Vannozzi MO; Armirotti A; Nicodemo M; Venturini M; Cavallini L
    J Clin Oncol; 2008 Dec; 26(34):5652-3; author reply 5653-4. PubMed ID: 18981458
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
    Lunardi G; Armirotti A; Nicodemo M; Cavallini L; Damonte G; Vannozzi MO; Venturini M
    Clin Ther; 2009 Aug; 31(8):1812-9. PubMed ID: 19808140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous Metastasis as a Presenting Feature of Renal Adenocarcinoma in a Renal Transplant Recipient: A Case Report.
    Basic-Jukic N; Mesar I; Kirincich J
    Transplant Proc; 2019 Nov; 51(9):3072-3073. PubMed ID: 31611123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma.
    Lamm W; Vogl UM; Bojic M; Zielinski C; Klingler C; Kramer G; Schmidinger M
    Acta Oncol; 2012 Jan; 51(1):101-6. PubMed ID: 21736504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany.
    Gerullis H; Bergmann L; Maute L; Eimer C; Otto T
    Cancer Chemother Pharmacol; 2009 May; 63(6):1097-102. PubMed ID: 18818922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.